Meet us at EASD 2023 in Hamburg, Germany, from 2 to 6 October 🌟
✨ We are proud to announce that from October 2 to 6 our CRS Colleagues will attend the 59th annual meeting from European Association for the Study of Diabetes e.V. (EASD) in Hamburg, Germany and are happy to meet you face to face. At the conference you can meet Prof. Dr. Thomas Forst, Dr. med. Edis… read more
Resuscitation Week at CRS Mannheim from 18. to 24. September 2023
Saving Lives, One Beat at a Time!💢 Life-saving First Aid Skills should not be brought to the attention or discussed only when the emergency situation comes up or has already occurred. At CRS Group, we are proud to support #CPRWeek with our Save a Life initiative! As part of this week, two sessions were organized… read more
From September 26-28, you can find us at BioSpain 2023 in Barcelona, Spain.
From September 26-28, you can find us at #BIOSPAIN2023 in Barcelona, Spain. The largest biotech event organized by a national bioindustry association in Europe, the event offers 800+ companies and 2000+ attendees the opportunity to collaborate and network. As experts in innovative clinical trial services, we also look forward to the opportunity to meet face-to-face… read more
Check out the study “First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.”
Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://pubmed.ncbi.nlm.nih.gov/35437837/ … read more
Check out the study “Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis”
Have you already read this interesting publication on ERJ Open Research? 📑 📢 Check out the study “Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis” to delve into the key findings and implications. We congratulate the team for their hard work and dedication!… read more
Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment”
Have you already read this interesting publication on Scientific Reports? 📑 📢 Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication… read more
Check out the study “Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant”
Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant” to delve into the key findings and implications. We congratulate the team for their hard work and dedication!… read more
Check out the study “Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment”
Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://pubmed.ncbi.nlm.nih.gov/36786053/ read more
Check out the study “Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity”
Have you already read the latest publication on PubMed ? Check out the study “Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here:… read more
Aktueller Stand der Forschung zu smarten Insulinen und deren Rolle in der Behandlung von Typ-2-Diabetes mit Prof. Dr. Forst
Wir freuen uns, Ihnen einen spannenden Podcast zu smarten Insulinen und dem aktuellen Stand in der Forschung präsentieren zu können. In dieser Folge von O-Ton-Diabetologie können Sie vom Prof. Dr. Forst mehr zu folgenden Themen erfahren: Was sind smarte Insuline und wie ist hier der aktuelle Stand der Forschung? Welche Rolle hat die Insulin-Therapie in… read more
Opening ceremony new unit Berlin – complete success!
The opening of our new location at the @TechnoCampus Berlin in Spandau was a complete success! The weather played along and we were able to celebrate a new chapter in our company history with our customers and befriended companies in a great atmosphere. And of course we would like to thank our colleagues and all… read more
25 Jahre CRS Kiel
Alles begann vor 25 Jahren… Am Freitag, den 28. April 2023, feiert CRS Kiel als ehemaliges „IKP – Institut für Klinische Pharmakologie Prof. Dr. Lücker“ 25-jähriges Firmenjubiläum. Wir freuen uns über diesen Erfolg und auf die nächsten Jahre! read more
Opening ceremony of our new location in Berlin
Dear friends of CRS Clinical Research Services GmbH, You are very welcome to attend the opening ceremony of our new location in Berlin. When? Thursday, April 20, 2023 12 to 20 pm Where? CRS Clinical Research Services Berlin TechnoCampus Berlin Siemensdamm 65 (Eingang Nikolaus-Groß-Weg) 13627 Berlin Please let us know by April 12, 2023 via… read more
Very soon – we are moving to Berlin’s TechnoCampus
The keys for our new Berlin facilities at the TechnoCampus will be handed over next week and the excitement couldn’t be greater! On March 1, the time has finally come and we will be able to welcome our business partners, healthy volunteers and patients at the new location! The date for our grand… read more
CRS Clinical Research Services Berlin zieht um.
CRS Clinical Research Services Berlin wird umziehen: von der Sellerstrasse 31 in Wedding in den modernen TechnoCampus am Berliner Siemensdamm. Wir sind glücklich darüber, unsere klinische Forschung dann in neuen, in jeder Hinsicht auf dem neuesten Stand und ganz nach unserem Bedarf ausgestatteten Räumen fortsetzen und robust für die Zukunft ausbauen zu können. In den… read more
First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.
Our partner Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes – a milestone! For more information, click here. read more
New Whitepaper: New strategies to improve clinical outcomes for diabetic kidney disease
Diabetes is a significant challenge for the global healthcare system: The International Diabetes Federation (IDF) estimates that healthcare expenditures already amount to USD 966 billion. In the coming years, the number of diabetics is expected to continue to increase significantly, and by 2045 it is estimated that 783 million people worldwide be living with the… read more
Herzinsuffizienz und Diabetes
Um auf die Häufigkeit und das zuweilen tödliche Zusammenspiel dieser Erkrankungen vermehrt aufmerksam zu machen, haben die Deutsche Diabetes Gesellschaft (DDG) und die Deutsche Gesellschaft für Kardiologie (DGK) ein erstes gemeinsames Positionspapier herausgegeben. Unser Geschäftsführer und Chief Medical Officer, Prof. Dr. Thomas Forst, war an dessen Ausarbeitung beteiligt Wir freuen uns, Ihnen den Link zur… read more
100 Jahre Insulin
2021 jährt sich zum hundertsten Mal ein zentrales Ereignis der Medizingeschichte: Die Isolierung von Insulin. Aus diesem Grund möchten wir Sie recht herzlich zum digitalen Event „100 Jahre Insulin“ einladen. Prof. Dr. Thomas Forst (Geschäftsführer & Chief Medical Officer bei CRS), wird mit seinem Vortrag „Ausblick: Grenzen der subkutanen Insulintherapie – wohin geht der Weg?“ zum… read more
Bayer AG and CRS Management GmbH extend strategic partnership
We are proud that the strategic partnership between Bayer AG and CRS Clinical Research Services Management GmbH, which has existed since 2013, has now been extended ahead of schedule, and we are pleased that we may continue to support Bayer AG as a reliable partner in its early clinical development. Bayer AG and CRS look… read more
emovis and CRS
We are proud to join forces with emovis GmbH in the development of COVID-19 treatments by offering combined clinical trials with healthy volunteers and SARS-CoV-2 patients. For more, see link below. https://www.emovis.de/en/services/covid-trial-unit/ read more